Work

Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients with Treatment-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)

Year: 2019

Type: article

Study design: Clinical Trial

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2019.07.293

Authors: Tycel Phillips, Stephen D. Smith, Wojciech Jurczak, Tadeusz Robak, Don A. Stevens, Charles M. Farber, John M. Pagel, Kami Maddocks, Ian Flinn, Wieslaw W. Jedrzejczak, Andre Goy, Pier Luigi Zinzani, Jan Zaucha, Morton Coleman, Tianling Chen, Sun Ku Lee, Wei Liang, Anna Seto, Michael Wang

Institutions: University of Michigan, University of Washington, Fred Hutch Cancer Center, Jagiellonian University, Copernicus Memorial Hospital, Medical University of Lodz, Norton Healthcare, Atlantic Health System, Swedish Medical Center, The Ohio State University, Sarah Cannon, Tennessee Oncology, Medical University of Warsaw, Hackensack University Medical Center, University of Bologna, Gdańsk Medical University, Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4235092023

FWCI: 0.18

Cites:

Cited by: 1

Related to: 10